Objective:

To address the contamination of drug products with diethylene glycol (DEG) and ethylene glycol (EG), highlight the importance of quality assurance in drug manufacturing, and acknowledge the public health risks associated with these contaminants.

Approach:

• Contamination Sources: DEG and EG can enter drug products as impurities during the manufacturing of sugar alcohols and through adulteration of excipients.
• Regulatory Requirements: US regulations mandate testing for impurities in raw materials, with additional guidance issued by the FDA in May 2023.
• Quality Assurance Standards: The USP provides standards and training for manufacturers to ensure the quality of excipients and drug components.

Key Findings:

• Over 300 deaths reported in 2022 and 2023 due to DEG and EG contamination in liquid drug products, including cough syrups and analgesics.
• Inadequate supplier qualification and lack of identity testing contribute to contamination risks.
• The FDA has issued over 40 warning letters regarding DEG and EG testing since 2019, with 33 in 2023 alone.
• Historical cases of DEG and EG contamination have resulted in serious public health concerns, including deaths and adverse health outcomes.

Interpretation:

The contamination of drug products with DEG and EG poses significant public health risks, particularly in low-to-middle-income countries with less stringent quality assurance.

Limitations:

• Low-to-middle-income countries may lack resources for adequate testing and quality assurance, hindering their ability to identify deadly contaminants.
• The complexity of the supply chain can hinder effective monitoring of drug components.

Conclusion:

The article emphasizes the need for rigorous testing and quality assurance in drug manufacturing to prevent contamination with toxic substances.

Sources:

• USP Guidance on Testing High-Risk Drug Components